ILT-2和ILT-4表达和供体基因型作为与HSCT结果相关的因素
Jagoda Siemaszko1, Piotr Łacina1, Donata Szymczak2
1Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Clinical immunology (Orlando, Fla.)
|October 4, 2025
概括
在全源造血干细胞移植 (HSCT) 中研究抑制受体免疫球蛋白样转录 (ILT) -2 和ILT-4 揭示了与移植结果的关联. 它们在自然杀手 (NK) 细胞上的表达可能会影响移植后的并发症,如移植对宿主疾病.
科学领域:
- 免疫学 免疫学 免疫学
- 移植科学 移植科学
- 细胞生物学 细胞生物学
背景情况:
- 自然杀手 (NK) 细胞在异构造血造干细胞移植 (HSCT) 后的活动仍然不完全理解.
- NK细胞功能由表面受体调节,包括ILT-2和ILT-4等抑制受体,这些受体在HSCT结果的背景下尚未得到广泛研究.
研究的目的:
- 研究免疫球蛋白样转录 (ILT) - 2和ILT - 4抑制受体在全基性HSCT中的作用.
- 探索ILT-2和ILT-4遗传变异和表面/mRNA表达与HSCT结果之间的关联,包括移植对宿主疾病 (GVHD) 和整体存活率.
主要方法:
- 对ILT-2和ILT-4多态的基因定型使用TaqMan试验进行.
- 在NK细胞上ILT-2和ILT-4的表面表达通过流细胞计量得到量化.
- 用ELISA测量可溶性HLA-F (sHLA-F) 和sHLA-G水平,并使用定量实时PCR评估ILT-2,ILT-4和干扰素- (IFN-γ) 的mRNA表达.
主要成果:
- 供体ILT-2 rs1061681 T等位基因与慢性GVHD (cGVHD) 的风险增加相关.
- 供体ILT-4 rs1128646 T等位基因与降低整体存活率和急性GVHD (aGvHD) 风险增加有关.
- 在aGvHD患者中,ILT-2 mRNA表达显著下降,ILT-4表达与IFN-γ表达呈负相关性. ILT-2和ILT-4的NK细胞表达峰值发生在HSCT后+21天左右.
结论:
- ILT-2和ILT-4抑制受体都与异性HSCT结果有显著的关联.
- 这些发现表明,NK细胞上ILT受体的表达可能在移植后并发症的发展中发挥关键作用.
相关概念视频
Tissue Transplantation
907
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
907
Bone Marrow Sampling and Transplants
881
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
881


